Open access
Oct 2026
Clinical Features and Outcomes of Therapy-Related Myeloid Neoplasms After CAR T-Cell Therapy.
Post-CAR-T t-MN carries an independent survival disadvantage not explained by TP53 clone burden; allogeneic HCT remains the only potentially curative option.
Michael D. Jain, Alaa Ali, Jaime Roman Diaz et al.
· Blood Advances · 0 citations